Press release
Wet Age-Related Macular Degeneration Pipeline 2024
Wet Age-related Macular Degeneration Pipeline
Key Takeaways from the Wet Age-Related Macular Degeneration Pipeline Report
• DelveInsight's Wet Age-Related Macular Degeneration pipeline report depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Wet Age-Related Macular Degeneration treatment.
• The leading companies working in the Wet Age-Related Macular Degeneration market include Molecular Partners, Sandoz, Sam Chun Dang Pharm, Samsung Bioepis, Opthea Limited, Shandong Boan Biotechnology Co. Ltd., Shanghai Henlius Biotech, Adverum Biotechnologies, Alkahest, Tyrogenex, Tasly Pharmaceutical Group, Ribomic, Innovent Biologics, GrayBug Vision, PanOptica, AsclepiX Therapeutics, AiViva BioPharma, RemeGen, Boehringer Ingelheim, Roche, Sunshine Guojian Pharmaceutical (Shanghai), Kyowa Kirin, Ocular Therapeutix, Shanghai Biomabs Pharmaceutical, Samjin Pharm, AffaMed Therapeutics, Novelty Nobility, Surrozen, Akari Therapeutics, Eyevensys, PharmAbcine, Evergreen Therapeutics, Ingenia Therapeutics, Ikarovec, Valitor, Character Biosciences, and others.
• Promising Wet Age-Related Macular Degeneration Pipeline Therapies in the various stages of development include Aflibercept (Eylea, BAY86-5321), Eyp-1901, NG101 AAV gene therapy, CMAB818, Lucentis®, RC28-E, Aflibercept, Ranibizumab, SCT510A, SCD411, Aflibercept, and others.
• October 2023: Neuracle Genetics Inc. announced a study of Phase 1 clinical trials for NG101 AAV gene therapy. This study will evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy administered by subretinal injections into a single selected eye as a single selected dose for patients with wet age-related macular degeneration (wAMD). This is a Phase 1/2a, multicenter, open-label, dose escalation study to evaluate the safety, tolerability, and preliminary efficacy of NG101 AAV gene therapy, administered by subretinal injection in patients with active wAMD symptoms. The study will be conducted at approximately 6 sites in Canada and the USA.
• October 2023: Sam Chun Dang Pharm Co. Ltd announced a study of Phase 3 clinical trials for SCD411 and Aflibercept. Age-related macular degeneration (AMD) is a leading cause of vision loss in adults. Abnormal blood vessels grow under the macula at the back of the eye, and also leak blood and fluid, which damages and scars the macula, affecting vision. The current standard of care for patients with neovascular (exudative / wet) AMD is anti-vascular endothelial growth factor (anti-VEGF) therapy, which prevents or slows down the growth of the abnormal blood vessels. SCD411 is being developed as a biosimilar to the reference product Eylea® (aflibercept), an anti-VEGF drug. The study aims to prove equivalence of SCD411 to Eylea in adults with wet AMD, and will look at safety, tolerance, effectiveness, immune response and the movement of the drug through the body.
Request a sample and discover the recent advances in Wet Age-Related Macular Degeneration Treatment Drugs @ Wet Age-Related Macular Degeneration Pipeline Outlook Report- https://www.delveinsight.com/report-store/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
The Wet Age-Related Macular Degeneration pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Wet Age-Related Macular Degeneration drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Wet Age-Related Macular Degeneration clinical trial landscape.
Wet Age-Related Macular Degeneration Overview
Age-related macular degeneration (AMD) is a multifactorial ocular disease that affects the maculae due to late-onset progressive neurodegeneration and dysfunction of photoreceptors and retinal pigment epithelium (RPE). Majorly, there are two types of AMD: dry (atrophic) and wet (neovascular or exudative).
Find out more about Wet Age-Related Macular Degeneration Treatment Drugs @ Drugs for Wet Age-Related Macular Degeneration Treatment- https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Wet Age-Related Macular Degeneration Emerging Drugs Profile
• Abicipar pegol: Molecular Partners
• SOK583A1: Sandoz
• BA9101 (LY09004): Shandong Boan Biotechnology Co. Ltd.
• ADVM-022: Adverum Biotechnologies
Wet Age-Related Macular Degeneration Pipeline Therapeutics Assessment
The Wet Age-Related Macular Degeneration pipeline report proffers an integral view of the Wet Age-Related Macular Degeneration emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
DelveInsight's Wet Age-Related Macular Degeneration Pipeline report covers around 80+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Wet Age-related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal
Wet Age-Related Macular Degeneration Pipeline Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule
Learn more about the emerging Wet Age-Related Macular Degeneration Pipeline Therapies @ Wet Age-Related Macular Degeneration Clinical Trials Assessment- https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Scope of the Wet Age-Related Macular Degeneration Pipeline Report
• Coverage- Global
• Encephalopathy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Encephalopathy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Wet Age-Related Macular Degeneration Companies- Molecular Partners, Sandoz, Sam Chun Dang Pharm, Samsung Bioepis, Opthea Limited, Shandong Boan Biotechnology Co. Ltd., Shanghai Henlius Biotech, Adverum Biotechnologies, Alkahest, Tyrogenex, Tasly Pharmaceutical Group, Ribomic, Innovent Biologics, GrayBug Vision, PanOptica, AsclepiX Therapeutics, AiViva BioPharma, RemeGen, Boehringer Ingelheim, Roche, Sunshine Guojian Pharmaceutical (Shanghai), Kyowa Kirin, Ocular Therapeutix, Shanghai Biomabs Pharmaceutical, Samjin Pharm, AffaMed Therapeutics, Novelty Nobility, Surrozen, Akari Therapeutics, Eyevensys, PharmAbcine, Evergreen Therapeutics, Ingenia Therapeutics, Ikarovec, Valitor, Character Biosciences, and others.
• Wet Age-Related Macular Degeneration Pipeline Therapies- Aflibercept (Eylea, BAY86-5321), Eyp-1901, NG101 AAV gene therapy, CMAB818, Lucentis®, RC28-E, Aflibercept, Ranibizumab, SCT510A, SCD411, Aflibercept, and others.
Dive deep into rich insights for new drugs for Wet Age-Related Macular Degeneration Treatment, Visit @ Wet Age-Related Macular Degeneration Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Table of Content
1. Introduction
2. Executive Summary
3. Wet Age-related Macular Degeneration: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Wet Age-related Macular Degeneration- DelveInsight's Analytical Perspective
7. Late Stage Products (Preregistration)
8. Abicipar pegol: Molecular Partners
9. Late Stage Products (Phase III)
10. SOK583A1: Sandoz
11. Drug profiles in the detailed report…..
12. Mid Stage Products (Phase II)
13. ADVM-022: Adverum Biotechnologies
14. Drug profiles in the detailed report…..
15. Early Stage Products (Phase I)
16. Drug Name: Company Name
17. Drug profiles in the detailed report…..
18. Preclinical and Discovery Stage Products
19. Drug Name: Company Name
20. Drug profiles in the detailed report…..
21. Inactive Products
22. Wet Age-related Macular Degeneration- Unmet Needs
23. Wet Age-related Macular Degeneration- Market Drivers and Barriers
24. Appendix
For further information on the Wet Age-Related Macular Degeneration Pipeline therapeutics, reach out to Wet Age-Related Macular Degeneration Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/wet-age-related-macular-degeneration-wet-amd-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
List of Important Links-
https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-market
https://www.delveinsight.com/report-store/glaucoma-market
https://www.delveinsight.com/report-store/uveitis-market
https://www.delveinsight.com/report-store/hemophilia-a2030-market
https://www.delveinsight.com/report-store/nephrotic-syndrome-market
https://www.delveinsight.com/report-store/short-bowel-syndrome-market
https://www.delveinsight.com/report-store/complement-3-glomerulopathy-c3g-market
https://www.delveinsight.com/report-store/retinitis-pigmentosa-market
https://www.delveinsight.com/report-store/aplastic-anemia-market
https://www.delveinsight.com/report-store/cystic-fibrosis-market
https://www.delveinsight.com/report-store/heart-failure-market
https://www.delveinsight.com/report-store/peanut-allergy-market
https://www.delveinsight.com/report-store/smoking-cessation-market
https://www.delveinsight.com/report-store/post-operative-pain-management-market
https://www.delveinsight.com/report-store/obstructive-sleep-apnea-osa-market
https://www.delveinsight.com/report-store/glioblastoma-multiforme-gbm-market
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Wet Age-Related Macular Degeneration Pipeline 2024 here
News-ID: 3406030 • Views: …
More Releases from DelveInsight Business Research LLP
Interstitial Lung Disease Pipeline Analysis, 2024: Clinical Trials, FDA, EMA, an …
DelveInsight's, "Interstitial Lung Diseases Pipeline Insight 2024" report provides comprehensive insights about 120+ companies and 120+ pipeline drugs in the Interstitial Lung Disease pipeline landscape. It covers the Interstitial Lung Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Interstitial Lung Disease pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
…
Glioma Pipeline Analysis, 2024: Clinical Trials, FDA, EMA, and PMDA Approvals, E …
DelveInsight's, "Glioma Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in the Glioma pipeline landscape. It covers the Glioma Pipeline Drug profiles, including clinical and nonclinical stage products. It also covers the Glioma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioma Pipeline Report
• DelveInsight's Glioma…
Glioblastoma Pipeline Analysis, 2024: Clinical Trials, FDA, EMA, and PMDA Approv …
DelveInsight's, "Glioblastoma Pipeline Insight 2024" report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in the Glioblastoma pipeline landscape. It covers the Glioblastoma pipeline drug profiles, including Glioblastoma clinical trials and nonclinical stage products. It also covers the Glioblastoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioblastoma Pipeline…
Gastric Cancer Pipeline Analysis, 2024: Clinical Trials, FDA, EMA, and PMDA Appr …
DelveInsight's, "Gastric Cancer Pipeline Insight 2024" report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Gastric Cancer pipeline landscape. It covers the pipeline drug profiles, including Gastric Cancer clinical trials and nonclinical stage products. It also covers the Gastric Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Gastric…
More Releases for Wet
Global Wet Cat Food Market and Trends
According to a new report published by Allied Market Research, titled, "Wet Cat Food Market by Product Type, End User, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2021-2030," The lockdown across various countries and ban on international travel has disrupted the supply chain and revenue chain.
The global wet cat food market size was valued at $4.6 billion in 2020, and is projected to reach $7.9 billion by 2030,…
Oscillation Flowmeters for Dry and Wet Gases
Oscillation is a measurement method that is unique for gases and can be used in a variety of ways for flow measurement with the aid of a flow oscillator. With this unique measuring method, a partial flow of the medium is passed through a bypass into the oscillator. In the oscillator, the medium flows through a chamber with two flow channels. A bluff body deflects the flow either in one…
Emirates Wet Wipes Partners with Medialinks
Emirates Wet Wipes, one of the largest hygiene care products manufacturers in the GCC, is ramping up its advertising and brand direction with the appointment of integrated digital & ecommerce agency, Medialinks, to its pan-Arab business.
Medialinks will be EWW’s first retained agency to oversee company’s entire digital account, which will encompass a fully optimized website, advertising, social, search engine optimisation and analytics.
The appointment happened after three-month competitive pitch process.…
Cross Fold Wet Tissue Market|| Worldwide, 2030
The “Cross Fold Wet Tissue Market Analysis to 2030” is a specialized and in-depth study of the Cross Fold Wet Tissue industry with a focus on the Cross Fold Wet Tissue market trend. The report aims to provide an overview of the Cross Fold Wet Tissue market with detailed market segmentation by component, application, end-user, and geography. The Cross Fold Wet Tissue market is expected to witness high growth during…
Global Cat Wet Food Market 2017 - NORY, WIK, Wanpy, Nature Bridge, WET NOSES
Apex Research, recently published a detailed market research study focused on the "Cat Wet Food Market" across the global, regional and country level. The report provides 360° analysis of "Cat Wet Food Market" from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global Cat Wet Food industry, and estimates the future trend of Cat…
Emerging Opportunities in Wet Macular Degeneration Market
Wet Macular Degeneration Market: Overview
Macular degeneration is a weakening or collapsed working of the eyes’ macula. Macula is the small area on the retinal surface covered by the light-sensitive tissue lining which is blackish area of the eye. This part of the retina is responsible for individual’s central vision, allows viewing fine objects clearly. Generally old aged people develop macular degeneration because of natural aging process of the body. There…
